692 related articles for article (PubMed ID: 28593615)
1. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
[TBL] [Abstract][Full Text] [Related]
2. Circulating ghrelin level is higher in HNF1A-MODY and GCK-MODY than in polygenic forms of diabetes mellitus.
Nowak N; Hohendorff J; Solecka I; Szopa M; Skupien J; Kiec-Wilk B; Mlynarski W; Malecki MT
Endocrine; 2015 Dec; 50(3):643-9. PubMed ID: 25987348
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
Pal A; Farmer AJ; Dudley C; Selwood MP; Barrow BA; Klyne R; Grew JP; McCarthy MI; Gloyn AL; Owen KR
Diabetes Care; 2010 Feb; 33(2):252-7. PubMed ID: 19933992
[TBL] [Abstract][Full Text] [Related]
4. A decision algorithm to identify patients with high probability of monogenic diabetes due to HNF1A mutations.
Szopa M; Klupa T; Kapusta M; Matejko B; Ucieklak D; Glodzik W; Zapala B; Sani CM; Hohendorff J; Malecki MT; Skupien J
Endocrine; 2019 Apr; 64(1):75-81. PubMed ID: 30778899
[TBL] [Abstract][Full Text] [Related]
5. Metabolic profiling in Maturity-onset diabetes of the young (MODY) and young onset type 2 diabetes fails to detect robust urinary biomarkers.
Gloyn AL; Faber JH; Malmodin D; Thanabalasingham G; Lam F; Ueland PM; McCarthy MI; Owen KR; Baunsgaard D
PLoS One; 2012; 7(7):e40962. PubMed ID: 22859960
[TBL] [Abstract][Full Text] [Related]
6. Insights from basic adjunctive examinations of GCK-MODY, HNF1A-MODY, and type 2 diabetes: A systemic review and meta-analysis.
Liu J; Xiao X; Zhang Q; Yu M
J Diabetes; 2023 Jun; 15(6):519-531. PubMed ID: 37226652
[TBL] [Abstract][Full Text] [Related]
7. Intima-media thickness and endothelial dysfunction in GCK and HNF1A-MODY patients.
Szopa M; Osmenda G; Wilk G; Matejko B; Skupien J; Zapala B; Młynarski W; Guzik T; Malecki MT
Eur J Endocrinol; 2015 Mar; 172(3):277-83. PubMed ID: 25501962
[TBL] [Abstract][Full Text] [Related]
8. Quality of life assessment in patients with HNF1A-MODY and GCK-MODY.
Szopa M; Matejko B; Ucieklak D; Uchman A; Hohendorff J; Mrozińska S; Głodzik W; Zapała B; Płatek T; Solecka I; Sani CM; Małecki MT
Endocrine; 2019 May; 64(2):246-253. PubMed ID: 30421137
[TBL] [Abstract][Full Text] [Related]
9. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
Kasichayanula S; Liu X; Pe Benito M; Yao M; Pfister M; LaCreta FP; Humphreys WG; Boulton DW
Br J Clin Pharmacol; 2013 Sep; 76(3):432-44. PubMed ID: 23210765
[TBL] [Abstract][Full Text] [Related]
10. Maturity Onset Diabetes of the Young (MODY) in Tunisia: Low frequencies of GCK and HNF1A mutations.
Ben Khelifa S; Martinez R; Dandana A; Khochtali I; Ferchichi S; Castaño L
Gene; 2018 Apr; 651():44-48. PubMed ID: 29408271
[TBL] [Abstract][Full Text] [Related]
11. HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults.
Fendler W; Borowiec M; Antosik K; Szadkowska A; Deja G; Jarosz-Chobot P; Mysliwiec M; Wyka K; Pietrzak I; Skupien J; Malecki MT; Mlynarski W
Clin Endocrinol (Oxf); 2011 Sep; 75(3):321-7. PubMed ID: 21521320
[TBL] [Abstract][Full Text] [Related]
12. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH
Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
[TBL] [Abstract][Full Text] [Related]
13. Co-inheritance of HNF1a and GCK mutations in a family with maturity-onset diabetes of the young (MODY): implications for genetic testing.
López-Garrido MP; Herranz-Antolín S; Alija-Merillas MJ; Giralt P; Escribano J
Clin Endocrinol (Oxf); 2013 Sep; 79(3):342-7. PubMed ID: 23009393
[TBL] [Abstract][Full Text] [Related]
14. Maturity Onset Diabetes of the Young due to Glucokinase, HNF1-A, HNF1-B, and HNF4-A Mutations in a Cohort of Turkish Children Diagnosed as Type 1 Diabetes Mellitus.
Ozsu E; Cizmecioglu FM; Yesiltepe Mutlu G; Yuksel AB; Calıskan M; Yesilyurt A; Hatun S
Horm Res Paediatr; 2018; 90(4):257-265. PubMed ID: 30481753
[TBL] [Abstract][Full Text] [Related]
15. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
[TBL] [Abstract][Full Text] [Related]
16. Three unreported glucokinase (GCK) missense mutations detected in the screening of thirty-two Brazilian kindreds for GCK and HNF1A-MODY.
Weinert LS; Silveiro SP; Giuffrida FM; Cunha VT; Bulcão C; Calliari LE; Della Manna T; Kunii IS; Dotto RP; Dias-da-Silva MR; Reis AF
Diabetes Res Clin Pract; 2014 Nov; 106(2):e44-8. PubMed ID: 25174781
[TBL] [Abstract][Full Text] [Related]
17. Maturity-onset diabetes of the young (MODY) in Brazil: Establishment of a national registry and appraisal of available genetic and clinical data.
Giuffrida FMA; Moises RS; Weinert LS; Calliari LE; Manna TD; Dotto RP; Franco LF; Caetano LA; Teles MG; Lima RA; Alves C; Dib SA; Silveiro SP; Dias-da-Silva MR; Reis AF;
Diabetes Res Clin Pract; 2017 Jan; 123():134-142. PubMed ID: 28012402
[TBL] [Abstract][Full Text] [Related]
18. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.
Besser RE; Shepherd MH; McDonald TJ; Shields BM; Knight BA; Ellard S; Hattersley AT
Diabetes Care; 2011 Feb; 34(2):286-91. PubMed ID: 21270186
[TBL] [Abstract][Full Text] [Related]
19. An Italian MODY family with proband and son carrying variants in GCK and HFN1A: is it a true case of digenic MODY?
Lucchesi D; Randazzo E; Del Prato S; Bianchi C
Acta Diabetol; 2024 Jan; 61(1):131-134. PubMed ID: 37730861
[TBL] [Abstract][Full Text] [Related]
20. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
McDonald TJ; Shields BM; Lawry J; Owen KR; Gloyn AL; Ellard S; Hattersley AT
Diabetes Care; 2011 Aug; 34(8):1860-2. PubMed ID: 21700917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
